Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naïve Patients With Castration-Resistant Prostate Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Takeda ( Millennium Pharmaceuticals, Inc. )
ClinicalTrials.gov Identifier:
NCT01666314
First received: August 6, 2012
Last updated: September 19, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2013
  Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: March 28, 2016